Data confirms mustard gas countermeasure efficacy

Biotechnology company Aeolus Pharmaceuticals, Inc., released data on Tuesday confirming the efficacy of a mustard gas medical countermeasure.

The data, gathered from studies funded by the CounterACT Program, the National Institutes of Health Office of the Director and the National Institute of Environmental Health Sciences, showed AEOL 10150 to be an effective treatment for both sulfur mustard gas inhalation and skin exposure from nitrogen mustard gas.

The studies found that AEOL 10150 treatment improved survival rates 24 hours after sulfur mustard gas inhalation from 42 to 94 percent. Survival rates in a 48-hour period improved to 88 percent from 35 percent.

AEOL 10150 treatment for nitrogen mustard gas skin exposure caused reductions in clinical lesions, including edema and wounded and wrinkled skin.

The treatment is a broad-spectrum catalytic antioxidant, and was developed specifically to neutralize reactive oxygen and nitrogen species, reducing oxidative stress, inflammation and subsequent tissue damage resulting from radiation exposure.

AEOL 10150 is also currently in development for use as a prophylactic and therapeutic treatment for cancer patients.

Aeolus Pharmaceuticals is developing AEOL 10150 with funding from the U.S. Department of Health and Human Services as a medical countermeasure against chemical and radiological weapons. The treatment is intended for use as a protective agent against acute radiation syndrome and delayed effects of acute radiation exposure.

Organizations in this Story

Aeolus Pharmaceuticals National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.